Clinical Trial Update: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase II study evaluating maintenance therapy with ivosidenib after standard-of-care adjuvant chemotherapy in curative IDH1-mutant cholangiocarcinoma; recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Tibsovo (ivosidenib) (ivosidenib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Cholangiocarcinoma, IDH Mutation | Phase 2 | Status: RECRUITING